We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.
Health conditions and diseases that the clinical trial is designed to study and treat.
Advanced Non-Small Cell Lung Cancer (NSCLC) refers to a type of lung cancer that has spread beyond the lungs and is typically not amenable to surgery. It is characterized by the presence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild type tumor pathology.
Post-Chemotherapy Urothelial Carcinoma refers to cancer of the urinary tract that persists or recurs after chemotherapy treatment. It can affect the bladder, ureters, and other parts of the urinary system.
Extensive Stage Small-Cell Lung Cancer (SCLC) is a fast-growing type of lung cancer that has spread beyond the lungs to other parts of the body. It is often diagnosed at an advanced stage.
Locally Advanced Non-Small Cell Lung Cancer (Stage III) is a type of lung cancer that has spread to nearby tissues or lymph nodes but has not yet metastasized to distant sites. It is often treated with a combination of chemotherapy and radiation.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
